TY  - JOUR
TI  - Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism
AB  - Introduction: Dipeptidyl peptidase-4 (DPP4) has been shown to be a functional receptor for MERS-CoV. An interaction between the viral spike protein and DPP4 is thought to facilitate viral entry. We aimed to find out whether sitagliptin, a member of DPP4 inhibitors, would have beneficial effects in COVID-19 patients. Materials and Methods: In this single center retrospective study, we evaluated 58 patients of whom 16 were on sitagliptin treatment. Molecular docking studies were performed to identify possible interactions between ACE2 and sitagliptin. Results: Sitagliptin use shortened the time to clinical recovery about 3.5 and fastened viral clearance more than 5 days. Resolution of all symptoms was achieved on a mean±standard error (SE) of 2.50 ± 0.40 days in sitagliptin (+) group and 5.69 ± 0.61 days in sitagliptin (-) group (Log-rank test, p< 0.001). PCR tests for SARS-CoV-2 resulted negative in mean ± SE of 7.50 ± 0.98 days in sitagliptin (+) and 13.17 ± 1.07 days in sitagliptin (-) group (Log-rank test, p= 0.003). Compared to day 0, CRP, ferritin and D-dimer levels on days three, five, and seven were significantly lower whereas lymphocyte count was higher in sitagliptin (+) group. Conclusion: Our results suggest that sitagliptin seems to have a potential to be considered for the treatment of COVID-19.
AU  - ELHAN, ATİLLA HALİL
AU  - CINAR, GULE
AU  - yazgan, coşkun
AU  - Karahan, Zeynep Ceren
AU  - Azap, Alpay
AU  - NAZIR, HASAN
AU  - UNAL, Mehmet Altay
AU  - Demir, Özgür
AU  - Akdemir Kalkan, İrem
AU  - Gülten, Ezgi
AU  - Birengel, Serhat
DO  - 10.5578/flora.20229816
PY  - 2022
JO  - Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi
VL  - 27
IS  - 2
SN  - 1300-932X
SP  - 324
EP  - 334
DB  - TRDizin
UR  - http://search/yayin/detay/1110216
ER  -